ecDNA is increasingly recognised as a major driver of oncogene amplification and intratumoural heterogeneity. What has been less clear is how other genomic sequences that accompany oncogenes onto ecDNA contribute to cancer progression. The present work addresses that gap by mapping the 3D architecture of MYC-bearing ecDNA circles and cataloguing 68 genomic sites that interact with these structures. These sites were enriched for transposable elements, pointing to a pattern of repeated co-amplification.
The researchers focused on a fragment derived from an ancient LINE element, L1M4a1—labelled EIE 14, which is co-amplified with MYC. Using a combination of CRISPR-based ecDNA capture, interference assays and reporter analyses, they confirm that this fragment is physically embedded within ecDNA, displays enhancer activity and is required for optimal cancer cell growth. Importantly, the element’s activity depends entirely on the ecDNA context; in an isogenic cell line where MYC amplification occurs on chromosomal homogenously staining regions, EIE 14 remains transcriptionally silent.
This context-specific activation highlights a striking feature of ecDNA, its permissive chromatin environment. While transposable elements in the genome are typically repressed, their relocation onto ecDNA appears to unlock latent regulatory potential. The spatial clustering of ecDNA circles, observed through advanced imaging, may further amplify these effects by promoting enhancer–oncogene interactions in both cis and trans.
The study suggests that even degenerate, non-mobilising remnants of ancient retrotransposons can acquire new functional relevance once repositioned on ecDNA. This framework parallels long-standing observations in cancer genetics, where inherited variation in noncoding enhancer elements modulates risk. Here, however, the regulatory switch is driven not by sequence variation alone but by physical excision and reconfiguration of oncogenic loci.
Perturbing EIE 14 reduced the fitness of MYC-driven colorectal cancer cells, although quantifying downstream MYC expression proved challenging due to ecDNA heterogeneity and rapid growth arrest following CRISPR interference. The results nonetheless argue that transposable elements on ecDNA can support malignant phenotypes. Reports of recurrent LINE-1 amplification on ecDNA in patient tumours further bolster the clinical relevance.
By integrating repetitive elements into their structure, ecDNAs tap into a vast reservoir of sequences capable of generating regulatory diversity. This mechanism echoes the evolutionary dynamics of bacterial plasmids, where transposons repeatedly reshape mobile genetic elements through cycles of insertion and recombination. In the context of human cancer, such processes could accelerate oncogene activation, fuel selection and contribute to therapy resistance.
Together, the findings position transposable elements on ecDNA as both potential biomarkers of tumour evolution and targets for intervention. As ecDNA continues to emerge as a key player in cancer biology, understanding how it repurposes the repetitive genome may open new avenues for diagnosis and therapeutic design.